Indian Council of Medical Research consensus document for the management of colorectal cancer

Bhawna Sirohi; Shailesh V. Shrikhande; Benjamin Perakath; Digumarti Raghunandharao; Pramod Kumar Julka; Vikram Lele; Arvind Chaturvedi; Ambakumar Nandakumar; M Ramadwar; Vikram Bhatia; Rohin Mittal; Tanvir Kaur; Deepak Kumar Shukla; Goura Kishor Rath

doi:10.4103/0971-5851.142031

Indian Journal of Medical and Paediatric Oncology, Inhaltsverzeichnis

CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2014; 35(03): 192-196
DOI: 10.4103/0971-5851.142031

POSITION PAPER

Indian Council of Medical Research consensus document for the management of colorectal cancer

Bhawna Sirohi

Department of Medical Oncology, Kiran Mazumdar Shaw Cancer Centre, Bangalore, Karnataka, India

,

Shailesh V. Shrikhande

Department of Surgical Oncology, Pathology, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Benjamin Perakath

Department of Colorectal Surgery, Christian Medical College, Vellore, Tamilnadu, India

,

Digumarti Raghunandharao

Homi Bhabha Cancer Hospital and Research Centre, Visakhapatnam, Andhra Pradesh, Maharashtra, India

,

Pramod Kumar Julka

Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India

,

Vikram Lele

Department of Nuclear Medicine, Jaslok Hospital, Mumbai, Maharashtra, India

,

Arvind Chaturvedi

Department of Radiodiagnosis, Rajiv Gandhi Cancer Institute, New Delhi, India

,

Ambakumar Nandakumar

National Cancer Registry Programme, Bangalore, Karnataka, India

,

M Ramadwar

Department of Surgical Oncology, Pathology, Tata Memorial Centre, Mumbai, Maharashtra, India

,

Vikram Bhatia

Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India

,

Rohin Mittal

Department of Colorectal Surgery, Christian Medical College, Vellore, Tamilnadu, India

,

Tanvir Kaur

Indian Council of Medical Research, New Delhi, India

,

Deepak Kumar Shukla

Indian Council of Medical Research, New Delhi, India

,

Goura Kishor Rath

Department of Radiation Oncology, All India Institute of Medical Sciences, New Delhi, India

› Institutsangaben

Abstract

als PDF herunterladen

PDF (339 kb)

Referenzen

References
1 GLOBOCAN 2012. Available from: http://www.globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=colorectal.[Last cited on 2014 Aug 24].
2 National Cancer Registry Programme, Indian Council of Medical Research: Three Year Report of Population Based Cancer Registries 2009-2011. Available from: http://www.pbcrindia.org/.[Last accessed on 2014 Jun 16].
3 Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 2009;360:1408-17.
4 Peeters M, Oliner KS, Price TJ, Cervantes A, Sobrero AF, Ducreux M, et al. Analysis of KRAS/NRAS mutations in phase 3 study 20050181 of panitumumab (pmab) plus FOLFIRI versus FOLFIRI for second-line treatment (tx) of metastatic colorectal cancer (mCRC). J Clin Oncol 2014;32 Suppl 3. [abstr LBA387]. Available from: http://www.meetinglibrary.asco.org/content/122548-143.[Last cited on 2014 Aug 28].
5 Tejpar S, Lenz HJ, Köhne CH, Heinemann V, Ciardiello F, Esser R, et al. Effect of KRAS and NRAS mutations on treatment outcomes in patients with metastatic colorectal cancer (mCRC) treated first-line with cetuximab plus FOLFOX4: New results from the OPUS study. J Clin Oncol 2014;32 Suppl 3.[abstr LBA444]. Available from: http://www.meetinglibrary.asco.org/content/121584-143.[Last cited on 2014 Aug 28].
6 Sobhani I, Tiret E, Lebtahi R, Aparicio T, Itti E, Montravers F, et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008;98:875-80.
7 Ruers TJ, Wiering B, van der Sijp JR, Roumen RM, de Jong KP, Comans EF, et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: A randomized study. J Nucl Med 2009;50:1036-41.
8 Herbertson RA, Scarsbrook AF, Lee ST, Tebbutt N, Scott AM. Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol 2009;64:225-37.
9 Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: A systematic review and economic evaluation. Health Technol Assess 2011;15:1-192, iii.
10 Edge B, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A. Editors. AJCC Cancer Staging Manual. 7 th ed. New York, NY: Springer; 2010. Available from: http://www.springer.com/medicine/surgery/book/978-0-387-88440-0.[Last cited on 2014 Aug 28].
11 André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol Off J Am Soc Clin Oncol 2009;27:3109-16.
12 Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, et al. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 2011;29:1465-71.
13 Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010;28:3219-26.
14 Qi Y, Stoddard D, Monson JR. Indications and techniques of transanal endoscopic microsurgery (TEMS). J Gastrointest Surg 2011;15:1306-8.
15 Quirke P, Steele R, Monson J, Grieve R, Khanna S, Couture J, et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009;373:821-8.
16 Sauer R, Becker H, Hohenberger W, Rödel C, Wittekind C, Fietkau R, et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004;351:1731-40.
17 Hofheinz RD, Wenz F, Post S, Matzdorff A, Laechelt S, Hartmann JT, et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: A randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012;13:579-88.
18 Tural D, Selcukbiricik F, Özturk MA, Yildiz O, Turna H, Erdamar S, et al. The relation between pathological complete response and clinical outcome in patients with rectal cancer. Hepatogastroenterology 2013;60:1365-70.
19 Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L, et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006;355:1114-23.
20 Des Guetz G, Nicolas P, Perret GY, Morere JF, Uzzan B. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010;46:1049-55.
21 Delaunoit T, Alberts SR, Sargent DJ, Green E, Goldberg RM, Krook J, et al. Chemotherapy permits resection of metastatic colorectal cancer: Experience from Intergroup N9741. Ann Oncol 2005;16:425-9.
22 Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 2006;24:4976-82.
23 Folprecht G, Gruenberger T, Bechstein WO, Raab HR, Lordick F, Hartmann JT, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: The CELIM randomised phase 2 trial. Lancet Oncol 2010;11:38-47.
24 Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 2004;239:818-25.
25 Vasen HF, Mecklin JP, Khan PM, Lynch HT. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991;34:424-5.